These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 28067568)

  • 1. Improving community prescribing of post-fracture denosumab after discharge.
    Wood H; Lewis H; Ward R; Solanki T; Fernando P
    Br J Hosp Med (Lond); 2017 Jan; 78(1):20-22. PubMed ID: 28067568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteoporosis management in Australian general practice: an analysis of current osteoporosis treatment patterns and gaps in practice.
    Naik-Panvelkar P; Norman S; Elgebaly Z; Elliott J; Pollack A; Thistlethwaite J; Weston C; Seibel MJ
    BMC Fam Pract; 2020 Feb; 21(1):32. PubMed ID: 32050909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prescription of anti-osteoporosis medications after hospitalization for hip fracture: a multicentre Italian survey.
    Gonnelli S; Caffarelli C; Iolascon G; Bertoldo F; Letizia Mauro G; Patti A; Nuti R
    Aging Clin Exp Res; 2017 Oct; 29(5):1031-1037. PubMed ID: 27943127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study.
    Hadji P; Papaioannou N; Gielen E; Feudjo Tepie M; Zhang E; Frieling I; Geusens P; Makras P; Resch H; Möller G; Kalouche-Khalil L; Fahrleitner-Pammer A
    Osteoporos Int; 2015 Oct; 26(10):2479-89. PubMed ID: 26018090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. After the fall: improving osteoporosis treatment following hip fracture.
    Kuiper BW; Graybill S; Tate JM; Kaufman N; Bersabe D
    Osteoporos Int; 2018 Jun; 29(6):1295-1301. PubMed ID: 29464276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Declining rates of osteoporosis management following fragility fractures in the U.S., 2000 through 2009.
    Balasubramanian A; Tosi LL; Lane JM; Dirschl DR; Ho PR; O'Malley CD
    J Bone Joint Surg Am; 2014 Apr; 96(7):e52. PubMed ID: 24695929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uptake and characteristics of zoledronic acid and denosumab patients and physicians in Ontario, Canada: impact of drug formulary access.
    Burden AM; Tadrous M; Calzavara A; Cadarette SM
    Osteoporos Int; 2015 May; 26(5):1525-33. PubMed ID: 25603794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective analysis of eligibility for denosumab in patients presenting with osteoporotic fractures and renal impairment treated by orthogeriatric service at Middlemore Hospital.
    Kang MY; Besley J; Sun T; Paul S
    N Z Med J; 2020 May; 133(1515):16-24. PubMed ID: 32438373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful knowledge translation intervention in long-term care: final results from the vitamin D and osteoporosis study (ViDOS) pilot cluster randomized controlled trial.
    Kennedy CC; Ioannidis G; Thabane L; Adachi JD; Marr S; Giangregorio LM; Morin SN; Crilly RG; Josse RG; Lohfeld L; Pickard LE; van der Horst ML; Campbell G; Stroud J; Dolovich L; Sawka AM; Jain R; Nash L; Papaioannou A
    Trials; 2015 May; 16():214. PubMed ID: 25962885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of treatment in Australian men following fracture.
    Otmar R; Henry MJ; Kotowicz MA; Nicholson GC; Korn S; Pasco JA
    Osteoporos Int; 2011 Jan; 22(1):249-54. PubMed ID: 20229198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
    Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
    Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Practice Patterns and Performance in U.S. Fracture Liaison Programs: An Analysis of >32,000 Patients from the Own the Bone Program.
    Dirschl DR; Rustom H
    J Bone Joint Surg Am; 2018 Apr; 100(8):680-685. PubMed ID: 29664856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Undertreatment with anti-osteoporotic drugs after hospitalization for fracture.
    Panneman MJ; Lips P; Sen SS; Herings RM
    Osteoporos Int; 2004 Feb; 15(2):120-4. PubMed ID: 14618302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypocalcaemia after denosumab in older people following fracture.
    Chen J; Smerdely P
    Osteoporos Int; 2017 Feb; 28(2):517-522. PubMed ID: 27682248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of denosumab in osteoporotic patients previously treated with other medications: a systematic review and meta-analysis.
    Fontalis A; Kenanidis E; Prousali E; Potoupnis M; Tsiridis E
    Expert Opin Drug Saf; 2018 Apr; 17(4):413-428. PubMed ID: 29350565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adherence to denosumab in the treatment of osteoporosis and its utilization in the Czech Republic.
    Fuksa L; Vytrisalova M
    Curr Med Res Opin; 2015; 31(9):1645-53. PubMed ID: 26121231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years.
    Ferrari S; Adachi JD; Lippuner K; Zapalowski C; Miller PD; Reginster JY; Törring O; Kendler DL; Daizadeh NS; Wang A; O'Malley CD; Wagman RB; Libanati C; Lewiecki EM
    Osteoporos Int; 2015 Dec; 26(12):2763-71. PubMed ID: 26068295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary-care prescribing of anti-osteoporotic-type medications following hospitalisation for fractures.
    McGowan BM; Bennett K; Marry J; Walsh JB; Casey MC
    Eur J Clin Pharmacol; 2011 Mar; 67(3):301-8. PubMed ID: 21104407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study.
    Papapoulos S; Lippuner K; Roux C; Lin CJ; Kendler DL; Lewiecki EM; Brandi ML; Czerwiński E; Franek E; Lakatos P; Mautalen C; Minisola S; Reginster JY; Jensen S; Daizadeh NS; Wang A; Gavin M; Libanati C; Wagman RB; Bone HG
    Osteoporos Int; 2015 Dec; 26(12):2773-83. PubMed ID: 26202488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Denosumab after 8 years.
    Reid IR
    Osteoporos Int; 2015 Dec; 26(12):2759-61. PubMed ID: 26475285
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.